RT Journal Article
T1 Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab.
A1 Saro, Cristina
A1 Ceballos, Daniel
A1 Muñoz, Fernando
A1 de la Coba, Cristóbal
A1 Aguilar, Maria Dolores
A1 Lazaro, Pablo
A1 Garcia-Sanchez, Valle
A1 Hernandez, Mariola
A1 Barrio, Jesus
A1 de Francisco, Ruth
A1 Fernandez, Luis I
A1 Barreiro-de Acosta, Manuel
AB Clinical trials have shown the efficacy of adalimumab in Crohn's disease, but the outcome in regular practice remains unknown. The aim of the study was to examine clinical status, quality of life, and work productivity of Crohn's disease patients receiving adalimumab for one year in the context of usual clinical practice. This was a prospective, observational study with a one-year follow-up. After baseline, Crohn's disease patients were evaluated at 1, 3, 6, 9, and 12 months after starting treatment with adalimumab. Outcome variables included: clinical status (measured with CDAI), quality of life (measured with EuroQoL-5D and IBDQ), and work productivity (measured with WPAI questionnaire). These outcome variables were compared using the Student's t test or Wilcoxon test for paired comparison data according to the data distribution. Statistical significance was set at two-sided p  The sample was composed of 126 patients (age [mean] 39.1 ± [standard deviation] 13.8 years; 51% male). Significant changes were observed during the follow-up period: CDAI decreased from [median] 194 ([25-75 percentiles] 121-269) to 48.2 (10.1-122.0) (p  In regular practice, adalimumab is clinically effective in the treatment of Crohn's disease patients and results in a significant improvement in quality of life and work productivity.
PB Sociedad Española de Patologia Digestiva
SN 1130-0108
YR 2016
FD 2016-10-22
LK http://hdl.handle.net/10668/10716
UL http://hdl.handle.net/10668/10716
LA en
NO Saro C, Ceballos D, Muñoz F, de la Coba C, Aguilar MD, Lázaro P, et al. Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab. Rev Esp Enferm Dig. 2017 Feb;109(2):122-129
DS RISalud
RD Apr 5, 2025